Fertility Focus, manufacturers of the OvuCore and OvuSense Pro family of fertility monitoring solutions, with class II medical device classification and 510(k)FDA clearance – has launched OvuFirst, a completely unique patented sensor designed to measure skin temperature, providing women with an understanding of when to try and conceive naturally, and enabling them to determine what issues they may have trying to conceive.
Fertility Focus, manufacturers of the OvuCore and OvuSense Pro family of fertility monitoring solutions, with class II medical device classification and 510(k)FDA clearance – has launched OvuFirst, a completely unique patented sensor designed to measure skin temperature, providing women with an understanding of when to try and conceive naturally, and enabling them to determine what issues they may have trying to conceive.
Foresight Group has been a strategic partner with Fertility Focus since their GBP1.25 million investment in 2019.
Joining the OvuSense fertility monitoring family which now supports couples from their first months trying to conceive right the way through to monitoring clinical treatment, OvuFirst is targeted at women who wish to monitor their ovulation and cycles in a convenient, non-invasive way. By wearing the clinically-proven sensor on the arm or wrist overnight, OvuFirst confirms a woman’s fertile window with over 90 per cent accuracy even if she has irregular cycles – making it the most accurate skin-worn sensor on the market. The OvuSense App then uses this information to provide women with a full eight-day fertile window at the start of their next cycle.
“We took our revolutionary OvuSense patented technology proven in over 190,000 cycles of use, and used it to develop and test the most accurate skin-worn fertility monitoring sensor available on the market,” says Fertility Focus CEO Robert Milnes. “We are proud to offer a convenient and easy-to-use solution to assist and support women during the early stages of their fertility journey, whether that is trying to start a family, or simply learning more about their bodies and cycles. There are so many people within our organisation, as well as with tremendous partners such as Foresight Group, who have not only encouraged but participated in our company’s growth and exciting trajectory for helping women conceive. Thank you to all.”
In a side-by-side study volunteers wore the OvuCore vaginal sensor and OvuFirst skin sensor overnight for several cycles. The study concluded that the skin-worn sensor provides a convenient method of determining the presence or absence of ovulation, even in women who have a known history of ovulatory dysfunction, anovulation (the absence of ovulation), and/or ‘abnormal’ long cycles. The study is expected to be published later in the year.
“I love how easy and comfortable OvuFirst is. OvuFirst provided me with a non-invasive way to collect data and see trends to better understand my personal health. As a medical provider who takes care of women’s health, I am looking forward to this being a wonderful resource for all women to understand, be informed, and empowered to take control of their health,” says Hina Mazharuddin, Physician’s Assistant — Certified, OvuFirst study participant.
“We are delighted to support Fertility Focus as the team enhance their current range of products with the launch of OvuFirst,” says Robert Jones, Senior Investment Manger at Foresight Group. “This convenient, easy to use device represents a huge milestone in non-invasive fertility monitoring, allowing more women access to highly effectively predictive technology to support their fertility journey. We look forward to working further with the team as they continue to operate at the forefront of the industry, developing market-leading products breaking down the complexities surrounding fertility.”
At the heart of the OvuSense fertility monitoring family is the ability to provide clinically proven, accurate and useful information so every woman can best understand her unique individual cycle pattern. Robert Milnes continues: “For almost a decade, OvuSense has been at the forefront of breaking down the mythology surrounding the concept of what constitutes a ‘normal’ cycle, showing for instance that although traditional thinking holds that a large majority of women ovulate mid-cycle, only around 40 per cent of OvuCore users show this pattern” OvuSense’s OvuCore works by measuring female continuous core body temperature (cCBT) using a sensor worn in the vagina overnight.
Further ground-breaking clinical research led to the development of OvuSense Pro, which provides doctors with detailed remote screening for potential causes of female sub-fertility, risk of miscarriage, and potential pregnancy complications. A presentation at the Vitalis conference in 2020 detailed the added benefit of OvuSense Pro through a number of case studies: Because it can show what’s happening throughout the cycle, women and their doctors can also use OvuSense Pro to track medications and treatment, and understand if these are improving the regularity of ovulation, and the chances of a successful pregnancy.
